Ikena Oncology Inc. said the U.S. Food and Drug Administration has granted Fast Track designation for IK-930 for patients with unresectable NF2-deficient malignant pleural mesothelioma.
Fast Track designation granted by the FDA facilitates the development and expedites the review of drugs intended to treat serious or life-threatening diseases.
Earlier in 2022, the FDA granted IK-930 Orphan Drug designation, which supports development of drugs for rare disorders, as a potential novel therapeutic option for patients with malignant pleural mesothelioma.
IK-930 is currently being studied in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.